Cisplatin-Associated Ototoxicity: A Review for the Health Professional
Cisplatin is an effective drug used in the treatment of many cancers, yet its ototoxic potential places cancer patients, exposed to this drug, at risk of hearing loss, thus negatively impacting further on a patient’s quality of life. It is paramount for health care practitioners managing such patien...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Toxicology |
| Online Access: | http://dx.doi.org/10.1155/2016/1809394 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567551289196544 |
|---|---|
| author | Jessica Paken Cyril D. Govender Mershen Pillay Vikash Sewram |
| author_facet | Jessica Paken Cyril D. Govender Mershen Pillay Vikash Sewram |
| author_sort | Jessica Paken |
| collection | DOAJ |
| description | Cisplatin is an effective drug used in the treatment of many cancers, yet its ototoxic potential places cancer patients, exposed to this drug, at risk of hearing loss, thus negatively impacting further on a patient’s quality of life. It is paramount for health care practitioners managing such patients to be aware of cisplatin’s ototoxic properties and the clinical signs to identify patients at risk of developing hearing loss. English peer-reviewed articles from January 1975 to July 2015 were assessed from PubMed, Science Direct, and Ebscohost. Seventy-nine articles and two books were identified for this review, using MeSH terms and keywords such as “ototoxicity”, “cisplatin”, “hearing loss”, and “ototoxicity monitoring”. This review provides an up-to-date overview of cisplatin-associated ototoxicity, namely, its clinical features, incidence rates, and molecular and cellular mechanisms and risk factors, to health care practitioners managing the patient with cancer, and highlights the need for a team-based approach to complement an audiological monitoring programme to mitigate any further loss in the quality of life of affected patients, as there is currently no otoprotective agent recommended routinely for the prevention of cisplatin-associated ototoxicity. It also sets the platform for effective dialogue towards policy formulation and strengthening of health systems in developing countries. |
| format | Article |
| id | doaj-art-d729a5974e0242eca8531742632b0195 |
| institution | Kabale University |
| issn | 1687-8191 1687-8205 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Toxicology |
| spelling | doaj-art-d729a5974e0242eca8531742632b01952025-02-03T01:01:12ZengWileyJournal of Toxicology1687-81911687-82052016-01-01201610.1155/2016/18093941809394Cisplatin-Associated Ototoxicity: A Review for the Health ProfessionalJessica Paken0Cyril D. Govender1Mershen Pillay2Vikash Sewram3Discipline of Audiology, School of Health Sciences, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South AfricaDiscipline of Audiology, School of Health Sciences, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South AfricaDiscipline of Audiology, School of Health Sciences, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South AfricaDiscipline of Audiology, School of Health Sciences, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South AfricaCisplatin is an effective drug used in the treatment of many cancers, yet its ototoxic potential places cancer patients, exposed to this drug, at risk of hearing loss, thus negatively impacting further on a patient’s quality of life. It is paramount for health care practitioners managing such patients to be aware of cisplatin’s ototoxic properties and the clinical signs to identify patients at risk of developing hearing loss. English peer-reviewed articles from January 1975 to July 2015 were assessed from PubMed, Science Direct, and Ebscohost. Seventy-nine articles and two books were identified for this review, using MeSH terms and keywords such as “ototoxicity”, “cisplatin”, “hearing loss”, and “ototoxicity monitoring”. This review provides an up-to-date overview of cisplatin-associated ototoxicity, namely, its clinical features, incidence rates, and molecular and cellular mechanisms and risk factors, to health care practitioners managing the patient with cancer, and highlights the need for a team-based approach to complement an audiological monitoring programme to mitigate any further loss in the quality of life of affected patients, as there is currently no otoprotective agent recommended routinely for the prevention of cisplatin-associated ototoxicity. It also sets the platform for effective dialogue towards policy formulation and strengthening of health systems in developing countries.http://dx.doi.org/10.1155/2016/1809394 |
| spellingShingle | Jessica Paken Cyril D. Govender Mershen Pillay Vikash Sewram Cisplatin-Associated Ototoxicity: A Review for the Health Professional Journal of Toxicology |
| title | Cisplatin-Associated Ototoxicity: A Review for the Health Professional |
| title_full | Cisplatin-Associated Ototoxicity: A Review for the Health Professional |
| title_fullStr | Cisplatin-Associated Ototoxicity: A Review for the Health Professional |
| title_full_unstemmed | Cisplatin-Associated Ototoxicity: A Review for the Health Professional |
| title_short | Cisplatin-Associated Ototoxicity: A Review for the Health Professional |
| title_sort | cisplatin associated ototoxicity a review for the health professional |
| url | http://dx.doi.org/10.1155/2016/1809394 |
| work_keys_str_mv | AT jessicapaken cisplatinassociatedototoxicityareviewforthehealthprofessional AT cyrildgovender cisplatinassociatedototoxicityareviewforthehealthprofessional AT mershenpillay cisplatinassociatedototoxicityareviewforthehealthprofessional AT vikashsewram cisplatinassociatedototoxicityareviewforthehealthprofessional |